CVS
CVS Health Corporation  |  NYSE
52wk high:106.67
52wk low:69.30
EPS:4.66
PE (ttm):17.59
Div Rate (fwd):1.70
Yield (fwd):2.07%
Market Cap:$87.43B
Volume:
  • Thu, Jan. 12, 4:13 PM
    • With the aim of addressing customers' anger over the high price of Mylan's (NASDAQ:MYL) EpiPen (epinephrine injection, USP), CVS Health (NYSE:CVS) says its pharmacies will sell a generic version of Amedra Pharmaceuticals' Adrenaclick, made by Impax Laboratories (NASDAQ:IPXL), for $109.99/two-pack, about the price EpiPen sold for eight years ago. Commercially insured patients are eligible to receive $100 coupon that will lower their out-of-pocket cost to $9.99. CVS will purchase the product directly from Impax.
    • It will continue to sell EpiPen for $649.00 and Mylan's generic version for $339.99.
    Thu, Jan. 12, 4:13 PM | 32 Comments
  • Sat, Jan. 7, 11:08 AM
    Sat, Jan. 7, 11:08 AM
  • Sat, Jan. 7, 11:04 AM
    • Retail execs head down to Florida next week for the closely-watched ICR Conference.
    • The confab this year arrives at a tumultous time for the sector. A wave of soft holiday period sales reports have set a negative tone amid increasing worries over Trump administration trades policies and border adjustment taxes.
    • Bloomberg Intelligence analyst Chen Grazutis wants to hear what apparel retailers say about the impact of moving sourcing back to the U.S. On the positive side, some labor wage fear have subsided and inventory levels are better than they were a year ago.
    • It's unlikely that Q&A at ICR won't delve into Amazon (NASDAQ:AMZN) and the ongoing impact of e-commerce on volume and margins.
    • Chipotle's (NYSE:CMG) presentation will be one of the bigger events in the restaurant sector, although investors might need their hard hats on with guidance updates/warnings expected from many food chains. Also keep an eye on how restaurant management talks about local sourcing and the shift toward eating local, trends which could bode well for Sysco (NYSE:SYY) and US Foods (NYSE:USFD), tips Bloomberg Intelligence.
    • ICR presenters: AEO, ANFI, AVP, BGS, BOJA, BOOT, CBRL, CHEF, CORE, CTRN, CVS, DENN, DFRG, DXLG, ELF, EXPR, FIVE, FRAN, FRPT, FTD, GCO, GIII, GPC, HOME, IRBT, JACK, JMBA, KONA, LNDC, LULU, MED, OLLI, OXM, PERY, PLAY, PLCE, PRMW, PRTS, PRTY, RUTH, SHAK, SMRT, SNAK, SODA, SPWH, SQBG, SSI, TACO, TAST, TWNK, UEIC, UNFI, USFD, VNCE, W, WING, WMAR, ZOES.
    • #ICR17
    Sat, Jan. 7, 11:04 AM | 12 Comments
  • Dec. 15, 2016, 7:49 AM
    • CVS Health (NYSE:CVS) updates its 2016 and 2017 guidance at its annual Analyst Day in New York.
    • 2016: EPS: $4.82 - 4.88; Non-GAAP EPS: $5.77 - 5.83; Cash Flow Ops: $9.1B - 9.3B; Free Cash Flow: $6.8B - 7.0B.
    • 2017: EPS: $5.02 - 5.18; Non-GAAP EPS: $5.77 - 5.93 (assumes completion of $5B in share buybacks in 2017); Cash Flow Ops: $7.7B - 8.6B; Free Cash Flow: $6.0B - 6.4B.
    • Board has approved an 18% increase in the annual dividend in 2017 ($2/share). $18B authorized for share repurchases over next five years.
    Dec. 15, 2016, 7:49 AM | 11 Comments
  • Dec. 15, 2016, 4:51 AM
    • CVS Health (NYSE:CVS) is scheduled to hold its Analyst Day event today amid the changing drugstore landscape with Walgreens (NASDAQ:WBA) and Rite Aid (NYSE:RAD) merging.
    • Jefferies expects CVS management to highlight the company's efforts to improve market share and cut costs, while  Barclays notes that details on product introductions and capital allocation will be crucial for investors.
    • Also watch for a 2017 guidance update from CVS. Consensus estimates currently stand at revenue of $187.8B and EPS of $5.87.
    Dec. 15, 2016, 4:51 AM
  • Dec. 14, 2016, 7:10 AM
    • Effective January 1, Eli Lilly (NYSE:LLY) and pharmacy benefit manager (PBM) Express Scripts (NASDAQ:ESRX) will offer discounts on some of Lilly's insulin products to patients who lack insurance or are in the deductible phase of their high-deductible insurance plans. The discounted prices, up to 40% in certain cases, will be available online and via mobile apps provided by Blink Health.
    • The program covers Humalog, Humulin and Basaglar.
    • Insulin makers have been criticized over pricing. Some have avoided working with PBMs which has eroded their market share. Lilly has worked with PBMs from the get go and it appears to be paying off. Earlier this year, CVS Health (NYSE:CVS) included Basaglar on its national formulary, prioritizing it over Sanofi's (NYSE:SNY) Lantus and Toujeo. Novo Nordisk (NYSE:NVO) has also felt the pinch. It, along with Sanofi, have cut staff in their diabetes units due to pricing pressures.
    Dec. 14, 2016, 7:10 AM | 2 Comments
  • Dec. 12, 2016, 2:55 PM
    • Jefferies analyst Brian Tanquilut says the catalysts to stoke CVS Health's (CVS -0.6%) growth over the next 12 months aren't there. He adds that losses in the retail pharmacy space and the overhang from investors' concerns about PMB contracting are the main impediments to a meaningful increase in valuation.
    • He rates the stock a Hold and reduces his price target to $82 (3% upside) from $122.
    • Five shops that recently updated coverage rate it a Buy with price targets ranging from $85 to $111.
    Dec. 12, 2016, 2:55 PM | 11 Comments
  • Nov. 23, 2016, 4:48 AM
    • If you use aloe vera gel from Walmart (NYSE:WMT), Target (NYSE:TGT) or CVS, you might be soothing burns with sugar rather than extract from a plant.
    • According to Bloomberg, multiple lab tests of the retailer's store-brand gel showed no traces of aloe vera, even though it's listed as the first or second ingredient in every case.
    • How could this happen? The FDA doesn't approve cosmetics before they hit store shelves, so it's up to suppliers to make good on their promises.
    Nov. 23, 2016, 4:48 AM | 21 Comments
  • Nov. 14, 2016, 8:00 AM
    • Barron's points to a handful of companies which could benefit significantly from a lower corporate tax rate in the future as a result of the GOP election sweep last week.
    • Altria Group (NYSE:MO), CSX (NYSE:CSX), Dollar General (NYSE:DG), Kohl's (NYSE:KSS) and CVS Health (NYSE:CVS) all paid out effective tax rates of over 36% during the last five years.
    Nov. 14, 2016, 8:00 AM | 42 Comments
  • Nov. 11, 2016, 4:57 PM
    • Albertsons and Kroger (NYSE:KR) have emerged as key prospective suitors for Walgreens (NASDAQ:WBA) in its attempts to find a way to satisfy the FTC's review of the company's proposed acquisition of Rite Aid (NYSE:RAD), while CVS (NYSE:CVS) seems to have withdrawn interest, CTFN reports.
    • Walgreens has not yet "freshened up the package" of store selloffs that it plans to present to the FTC, according to the report, which cites an antitrust attorney, who also says that "Albertsons and Kroger are established retail players with experience in pharmacies" and that the assets they are eyeing represent "key geographic expansion for both."
    Nov. 11, 2016, 4:57 PM | 79 Comments
  • Nov. 8, 2016, 9:17 AM
    Nov. 8, 2016, 9:17 AM
  • Nov. 8, 2016, 8:31 AM
    • CVS Health (CVS) Q3 results: Revenues: $44,615M (+15.5%); Operating Income: $2,817M (+20.8%); Net Income: $1,542M (+24.7%); EPS: $1.43 (+30.0%); Non-GAAP EPS: $1.64 (+28.1%); Quick Assets: $2,263M (-11.2%); CF Ops: $7,948M (+64.2%).
    • Q4 Guidance: GAAP EPS: $1.52 - 1.58; Adjusted EPS: $1.64 - 1.70.
    • 2016 Guidance: GAAP EPS: $4.84 - 4.90 from $4.92 - 5.00; Adjusted EPS: $5.77 - 5.83 from $5.81 - 5.89; CF Ops: $9.3B- 9.5B; FCF: $6.8B - 7.0B.
    • 2017 Preliminary Outlook: GAAP EPS: $5.16 - 5.33; Non-GAAP EPS: $5.77 - 5.93.
    • Shares are down 15% premarket.
    Nov. 8, 2016, 8:31 AM | 53 Comments
  • Nov. 8, 2016, 6:56 AM
    • CVS Health (NYSE:CVS): Q3 EPS of $1.64 beats by $0.07.
    • Revenue of $44.62B (+15.5% Y/Y) misses by $670M.
    • Press Release
    Nov. 8, 2016, 6:56 AM | 73 Comments
  • Nov. 7, 2016, 5:30 PM
  • Nov. 3, 2016, 10:18 AM
    • According to NBC, CVS Health (CVS +0.4%) has begun what it terms "a massive layoff" of employees, many at the company's main headquarters. Apparently, the move is a surprise to the workers as many are upset and panicking over whether they still have a job.
    Nov. 3, 2016, 10:18 AM | 33 Comments
  • Nov. 3, 2016, 8:24 AM
    Nov. 3, 2016, 8:24 AM | 43 Comments